Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
Standard
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". / Nast, Alexander; Augustin, Matthias; Boehncke, Wolf-Henning; Klaus, Joachim; Mrowietz, Ulrich; Ockenfels, Hans-Michael; Philipp, Sandra; Reich, Kristian; Rosenbach, Thomas; Schlaeger, Martin; Sebastian, Michael; Sterry, Wolfram; Streit, Volker; Weisenseel, Peter; Rzany, Berthold.
In: J DTSCH DERMATOL GES, Vol. 8, No. 1, 1, 2010, p. 65-66.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
AU - Nast, Alexander
AU - Augustin, Matthias
AU - Boehncke, Wolf-Henning
AU - Klaus, Joachim
AU - Mrowietz, Ulrich
AU - Ockenfels, Hans-Michael
AU - Philipp, Sandra
AU - Reich, Kristian
AU - Rosenbach, Thomas
AU - Schlaeger, Martin
AU - Sebastian, Michael
AU - Sterry, Wolfram
AU - Streit, Volker
AU - Weisenseel, Peter
AU - Rzany, Berthold
PY - 2010
Y1 - 2010
N2 - In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
AB - In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.
M3 - SCORING: Zeitschriftenaufsatz
VL - 8
SP - 65
EP - 66
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 1
M1 - 1
ER -